News
SLXN
1.310
-12.67%
-0.190
Silexion Therapeutics Secures Continued Nasdaq Listing Approval
TipRanks · 1d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 2d ago
Weekly Report: what happened at SLXN last week (1109-1113)?
Weekly Report · 4d ago
Silexion Q3 Net Loss Narrows To $2.5 Mln; First Patient Dosed In SIL204 Phase 2/3 Trial
NASDAQ · 11/13 17:56
Silexion Therapeutics GAAP EPS of -$13.70
Seeking Alpha · 11/13 16:31
*Silexion Therapeutics 3Q Net $2.53M >SLXN
Dow Jones · 11/13 14:04
Press Release: Silexion Therapeutics Reports -2-
Dow Jones · 11/13 14:03
Silexion Therapeutics Completes 1-for-24 Reverse Share Split
TipRanks · 11/12 21:40
Silexion Therapeutics Corp trading halted, news pending
TipRanks · 11/11 00:50
Silexion Sets 1-For-24 Reverse Share Split To Regain Nasdaq Compliance
NASDAQ · 11/09 13:13
Silexion Announces Reverse Share Split to Address Nasdaq Compliance
TipRanks · 11/09 12:48
Silexion Therapeutics Announces 1-For-24 Reverse Share Split, Trading On Split-Adjusted Basis To Begin On November 11
Benzinga · 11/09 12:13
Weekly Report: what happened at SLXN last week (1102-1106)?
Weekly Report · 11/09 10:09
Weekly Report: what happened at SLXN last week (1026-1030)?
Weekly Report · 11/02 10:08
Silexion registers to sell 8.81M ordinary shares for holders
TipRanks · 10/28 20:16
Silexion Therapeutics Shareholders Approve Major Capital Restructuring
TipRanks · 10/26 20:31
Weekly Report: what happened at SLXN last week (1019-1023)?
Weekly Report · 10/26 10:08
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/23 21:05
Weekly Report: what happened at SLXN last week (1012-1016)?
Weekly Report · 10/19 10:08
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/16 21:05
More
Webull provides a variety of real-time SLXN stock news. You can receive the latest news about Silexion Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About SLXN
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.